Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Emma Reeve
AddedMar 31, 2024
UpdatedMay 31, 2026
Emma Reeve

Emma Reeve

Board Member, Whitehawk Therapeutics

LinkedIn

Emma Reeve's Career

Whitehawk Therapeutics
Whitehawk Therapeutics

Pacific Grove, CA, US

Board Member· Board
Editas Medicine
Editas Medicine

Cambridge, MA, US

Board Member· Board
PTC Therapeutics
PTC Therapeutics

South Plainfield, NJ, US

Board Member· Board
Ribon Therapeutics
Ribon Therapeutics

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Emma Reeve's Career

Whitehawk Therapeutics
Whitehawk Therapeutics
Public$250.5M832011Pacific Grove, CA, US
Board Member· Board

Leadership at Whitehawk Therapeutics

Neil DesaiNeil DesaiBoard Member
Karin HehenbergerKarin HehenbergerBoard Member
Scott GiacobelloScott GiacobelloCEO
Richard MarounRichard MarounBoard Member
Caley CasteleinCaley CasteleinBoard Member

Similar to Whitehawk Therapeutics

A2 BiotherapeuticsA2 BiotherapeuticsAgoura Hills, CA, USCancer Treatmentest. 2018A2 BiotherapeuticsAgoura Hills, CA, US · est. 2018

A2: Advancing science to transform medicine, focusing on cell therapy for solid tumors.

Series B · $190.5M148
Fore BiotherapeuticsFore BiotherapeuticsPhiladelphia, PA, USCancer Therapiesest. 2011Fore BiotherapeuticsPhiladelphia, PA, US · est. 2011

Pioneering precision oncology firm, developing innovative, genomics-guided cancer therapies.

Series D · $166.5M45
Editas Medicine
Editas Medicine
Public$931.6M2262013Cambridge, MA, US
Board Member· Board

Leadership at Editas Medicine

J. Keith JoungJ. Keith JoungBoard Member
David R. LiuDavid R. LiuBoard Member
Akshay VaishnawAkshay VaishnawBoard Member
Gilmore O’NeillGilmore O’NeillBoard Member
Feng ZhangFeng ZhangBoard Member
Meeta ChatterjeeMeeta ChatterjeeBoard Member
PTC Therapeutics
PTC Therapeutics
Public$1.6B1.4k1998South Plainfield, NJ, US
Board Member· Board

Leadership at PTC Therapeutics

Matthew KleinMatthew KleinCEO
Glenn D. SteeleGlenn D. SteeleBoard Member
David SouthwellDavid SouthwellBoard Member
Allan JacobsonAllan JacobsonBoard Member
Jerome B. ZeldisJerome B. ZeldisBoard Member
Stuart W. PeltzStuart W. PeltzBoard Member

Similar to PTC Therapeutics

Amicus TherapeuticsAmicus TherapeuticsCranbury, NJ, USBiopharmaceuticalsest. 2002Amicus TherapeuticsCranbury, NJ, US · est. 2002

Amicus Therapeutics, a US-based public biopharmaceutical company, specializes in innovative medical solutions.

Public · $2.4B484
Sarepta TherapeuticsSarepta TherapeuticsCambridge, MA, USGene Therapiesest. 1980Sarepta TherapeuticsCambridge, MA, US · est. 1980

Sarepta Therapeutics, a US-based biopharmaceutical firm, specializes in medical research and drug development.

Public · $1.4B1.2k
BioCryst PharmaceuticalsBioCryst PharmaceuticalsDurham, NC, USPharmaceuticalsest. 1986BioCryst PharmaceuticalsDurham, NC, US · est. 1986

BioCryst Pharmaceuticals: A global biotech firm innovating oral treatments for rare diseases.

Public · $1.8B531
United TherapeuticsUnited TherapeuticsSilver Spring, MD, USPharmaceuticalsest. 1996United TherapeuticsSilver Spring, MD, US · est. 1996

United Therapeutics, a Maryland-based biotech firm, develops pharmaceuticals for vascular diseases using synthetic prostacyclin.

Public985
Ribon Therapeutics
Ribon Therapeutics
Series B$259M572015Cambridge, MA, US
Board Member· Board

Leadership at Ribon Therapeutics

Jon RootJon RootBoard Member
Jeff GoaterJeff GoaterBoard Member
Peter SvennilsonPeter SvennilsonBoard Member
Jodie MorrisonJodie MorrisonBoard Member
Paul ChangPaul ChangCo-Founder
Jim AudiaJim AudiaBoard Member

Similar to Ribon Therapeutics

RibonovaRibonovaWynnewood, PA, USPharmaceuticalsest. 2011RibonovaWynnewood, PA, US · est. 2011

US-based Ribonova Inc, founded in 2011, specializes in manufacturing pharmaceuticals for human and veterinary use.

Angel · $25k5
RibometrixRibometrixGreenville, NC, USDrug Discoveryest. 2014RibometrixGreenville, NC, US · est. 2014

Ribometrix, a US-based biotech firm, leverages 3D RNA analysis for novel drug discovery.

Series A · $45.3M29
ENB TherapeuticsENB TherapeuticsNew York City, NY, USCancer Therapeuticsest. 2015ENB TherapeuticsNew York City, NY, US · est. 2015

ENB Therapeutics, Inc.: A US-based biopharmaceutical firm developing novel inhibitors to treat cancers.

Series A · $8.2M8
Redona TherapeuticsRedona TherapeuticsWatertown, MA, USCancer Treatmentest. 2016Redona TherapeuticsWatertown, MA, US · est. 2016

Redona Therapeutics: Advancing small molecule therapies for cancer via ncRNA modulation.

Series A · $66.8M24

Emma Reeve's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Emma Reeve

Kevin J BittermanKevin J BittermanBoard Member · Morphic TherapeuticJim MullenJim MullenBoard Member · Thermo Fisher thElizabeth A HolmesElizabeth A HolmesBoard Member · TheranosTroy CoxTroy CoxBoard Member · LetsGetCheckedEd KaniaEd KaniaBoard Member · Flagship Pioneering